NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has signed an agreement to serve as worldwide distributor of Olink Bioscience's Duolink In Situ products.
The Duolink In Situ products enable researchers to image the locations of single protein-protein interactions, measure protein expression levels, and identify relative changes in post-translational modification events.
The products work in tandem with Sigma Life Science's antibody portfolio to enable researchers to target precise proteins of interest, said Sigma. In addition, the Duolink products can be used in combination with Sigma's CompoZr Zinc Finger Nuclease-mediated gene editing technology to track knocked-out or knocked-in genes, as well as with Sigma's Mission RNA interference technologies for tracking protein expression after gene knockdown.
"The ability to visualize these protein-protein interactions in unmodified cells under endogenous expression and at very low levels is a fundamental advance that allows greater insight into basic biology, pathways, spatial phenomena, and potential therapeutic targets in those pathways," Josef Zihlmann, VP of Sigma Life Science, said in a statement.
Simon Fredriksson, CEO and president of Uppsala, Sweden-based Olink, said that the alliance "will build awareness and develop the market for Duolink In Situ" through Sigma's global sales reach.
Further terms of the agreement were not disclosed.